Targeted alpha anticancer therapies: update and future prospects - Wikidata - wikimedia - TriplyDB

Targeted alpha anticancer therapies: update and future prospects

Targeted alpha anticancer therapies: update and future prospects

http://www.wikidata.org/entity/Q34511439

about

Safety and Outcome Measures of First-in-Human Intraperitoneal α Radioimmunotherapy With 212Pb-TCMC-Trastuzumab.A review of the development of tumor vasculature and its effects on the tumor microenvironment.Targeted alpha therapy using a novel CD70 targeted thorium-227 conjugate in in vitro and in vivo models of renal cell carcinoma.Targeted α Therapies for the Treatment of Bone Metastases.

P2860

Q30490448-B086418D-931D-4442-A6A5-011CA6BCEE95 Q38819800-BBDF6876-3045-46C9-9EC7-BB02979E91B8 Q41346916-0DF1C66A-5C81-4022-A847-57859A5E76C7 Q49271846-D54314E0-2CAF-43F4-8017-15391EB41054

P2860

Targeted alpha anticancer therapies: update and future prospects

http://www.wikidata.org/entity/Q34511439

description

2014 nî lūn-bûn

@nan

2014 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Targeted alpha anticancer therapies: update and future prospects

@ast

Targeted alpha anticancer therapies: update and future prospects

@en

Targeted alpha anticancer therapies: update and future prospects

@nl

type

label

Targeted alpha anticancer therapies: update and future prospects

@ast

Targeted alpha anticancer therapies: update and future prospects

@en

Targeted alpha anticancer therapies: update and future prospects

@nl

prefLabel

Targeted alpha anticancer therapies: update and future prospects

@ast

Targeted alpha anticancer therapies: update and future prospects

@en

Targeted alpha anticancer therapies: update and future prospects

@nl

P1433

Q34511439-E2E2CB1F-202C-49CD-BFEF-BDB40B351C0F

P1476

Q34511439-6AF8A27F-2957-46C4-A983-6F56455C4798

P2093

Q34511439-092A79BA-D80D-454D-A7A4-C6C0391FB2A0

Q34511439-99954226-D052-41A1-BDF6-00BCD6DD69ED

Q34511439-FF0DE8D1-2512-4247-99C7-37F3AFA2B8A7

P2860

Q34511439-08778759-66B0-4A06-9AFA-0AE38D4D8187

Q34511439-0AA024E3-8C3D-4E4D-9187-A0BF5CAA4A65

Q34511439-0AB50363-7D62-4F34-AAB4-81AF728ACE1B

Q34511439-155ED416-39EE-42B2-B05B-F7255730A8E2

Q34511439-228DA9DC-2DE6-468E-AA2F-181B043C52A3

Q34511439-2BFF8A05-3C92-4821-AA2A-5D601BFAC3ED

Q34511439-2D201BDC-F771-4E29-A149-7FBF644F3F82

Q34511439-364F485B-70D2-4B18-9074-E668693131DF

Q34511439-3668D3C6-ED5F-4F90-9CB5-03C8355554A7

Q34511439-38E256D8-3FCB-496F-A7E1-E8DC94DF29AE

P304

Q34511439-7070930C-957B-47EB-BA36-64598154316D

P31

Q34511439-3A0F256C-7C7D-45AC-8517-0BE03F08F95E

P356

Q34511439-FF1099AF-9146-45DC-BC51-7D3135C028A7

P478

Q34511439-186F66D1-B3C3-40ED-B8A0-E092F2266634

P577

Q34511439-36AF81F3-F865-4DF6-B22C-2807C98218E6

P5875

Q34511439-0C90987B-CAA5-4D64-9F84-88D55B8826F2

P698

Q34511439-88FDA416-CF77-4F99-A2B1-1E953FD49270

P932

Q34511439-FA643A62-39CF-4E2F-9363-4DB6F6FB520B

P356

P1433

Biologics: Targets and Therapy

P1476

Targeted alpha anticancer therapies: update and future prospects

@en

P2093

Barry J Allen

http://www.w3.org/2001/XMLSchema#string

Chen-Yu Huang

http://www.w3.org/2001/XMLSchema#string

Raymond A Clarke

http://www.w3.org/2001/XMLSchema#string

P2860

Continuous cultures of fused cells secreting antibody of predefined specificity

Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature

The radiation-induced bystander effect: evidence and significance

Alpha emitter radium-223 and survival in metastatic prostate cancer

Phase II study of Lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for metastatic castration-resistant prostate cancer.

Clinical experience with alpha-particle emitting 211At: treatment of recurrent brain tumor patients with 211At-labeled chimeric antitenascin monoclonal antibody 81C6

Phase I pharmacokinetic and biodistribution study with escalating doses of ²²³Ra-dichloride in men with castration-resistant metastatic prostate cancer.

Tumor therapy with targeted atomic nanogenerators.

Sequential cytarabine and alpha-particle immunotherapy with bismuth-213-lintuzumab (HuM195) for acute myeloid leukemia.

Conventional and pretargeted radioimmunotherapy using bismuth-213 to target and treat non-Hodgkin lymphomas expressing CD20: a preclinical model toward optimal consolidation therapy to eradicate minimal residual disease.

P304

255-267

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2147/BTT.S29947

http://www.w3.org/2001/XMLSchema#string

P478

8

http://www.w3.org/2001/XMLSchema#string

P577

2014-11-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

274733385

http://www.w3.org/2001/XMLSchema#string

P698

25422581

http://www.w3.org/2001/XMLSchema#string

P932

4232037

http://www.w3.org/2001/XMLSchema#string